Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Inclusion Criteria:

* Males or females with advanced, recurrent or metastatic cancer, refractory to standard therapy;
* Age ≥18 years;
* Signed informed consent form and ability to understand the study procedures.

Exclusion Criteria:

* Concomitant anticancer therapy, including radiation;
* Current or previous (within 30 days of first study dosing) treatment with another investigational drug or participation in another clinical study;
* Chronic daily treatment with aspirin (\>325 mg/day) or clopidogrel (\>75 mg/day);
* Chronic daily treatment with corticosteroids, with the exception of inhaled steroids;
* Inadequate bone marrow function;
* Inadequate liver function;
* Inadequate renal function;
* Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) \>1.5 or an activated partial thromboplastin time (aPTT) \>1.5 x ULN within 7 days prior to first study treatment;
* Patients with lymphomas;
* Evidence of spinal cord compression or brain metastases;
* Other malignancy diagnosed within the previous 5 years;
* Pregnant or lactating females.;
* All patients who do not use a highly effective method of birth control;
* Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment;
* Minor surgical procedures, within 24 hours prior to the first study treatment;
* History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding;
* Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular disease;
* History of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment;
* Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel;
* Serious non-healing wound, peptic ulcer or bone fracture;
* Known hypersensitivity to the study medication or any of its excipients;
* Evidence of any other medical conditions that may interfere with the planned treatment, affect patient compliance or place the patient at high risk of treatment-related complications;
* Previous enrollment in this study;
* Known hepatitis B or C or HIV infection;
* Employees of the sponsor or patients who are employees or relatives of the investigator.